Anti-LAIR1 Antibody(Eli Lilly)

PALO ALTO, Calif.--(BUSINESS WIRE)-- Immune-Onc Therapeutics Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today its plans to present on the company’s myeloid biology research and clinical stage programs at three upcoming scientific and investor conferences in March. The presentations will highlight the potential of Immune-Onc’s pipeline of first-in-class myeloid checkpoint inhibitors to transform current treatment approaches for blood cancers and solid tumors. Keystone Symposia: Cancer Immunotherapy: Mechanisms of Response Versus Resistance Date: Sunday, March 5 – Thursday, March 9 Location: Alberta, Canada At the prestigious Keystone Symposia on Cancer Immunotherapy, Immune-Onc’s Scientific Founder Dr. Chengcheng Alec Zhang will join the company's Chair of the Scientific Advisory Board (SAB), Dr. Michael Karin and Senior Director of Translational Research, Dr. Xiao Min Schebye for a series of pivotal presentations highlighting foundational research and insights driving our evolving understanding of mechanisms of response and resistance to cancer immunotherapy, and in particular, the LILRB family of immune inhibitory receptors as a promising class of therapeutic targets. Oral Presentation Details: Date: Monday, March 6 Presenter: Dr. Michael Karin, Immune-Onc SAB chair and professor of pharmacology at University of California, San Diego Title: Inflammation and Cancer: A Double-Edged Sword Oral Session: Dysfunctional Immune Cells in the TME Date: Wednesday, March 8 Presenter: Dr. Xiao Min Schebye, senior director of translational research at Immune-Onc Title: Anti-LAIR1 Antagonistic Antibodies Block Collagen-mediated Suppression of T Cell Activation Oral Session: Workshop 2 Date: Wednesday, March 8 Presenter: Dr. Chengcheng Alec Zhang, scientific founder of Immune-Onc and the Morton H. Sanger Professorship in Oncology and Michael L. Rosenberg Scholar for Biomedical Research at University of Texas Southwestern Medical Center Title: LILRBs - Myeloid Checkpoint Targets for Cancer Treatment Oral Session: Innate Immune Pathways and the Anti-Tumor Response 2nd Year Anniversary Symposium of the Myeloid Network Date: Thursday, March 9 from 11:00 a.m. - 2:30 p.m. ET Title: Novel Myeloid Checkpoint Inhibitors as Next Generation Cancer Immunotherapy Location: Virtual Charlene Liao, Ph.D., founder, chief executive officer and board chair of Immune-Onc will present an overview of the company’s work advancing the field of myeloid checkpoint inhibitors at the 2nd Year Anniversary Symposium of the Myeloid Network. The Myeloid Network seeks to connect researchers worldwide to promote communication and advancement of research and medicine in the field of myeloid cell biology. “I think your work represents the biotechnology industry outstandingly and I would love to feature your work as the final talk of our annual symposium,” said Judith Varner, Ph.D., co-founder of the Myeloid Network, professor of pathology and medicine and co-leader in solid tumor therapeutics at UC San Diego’s Moores Cancer Center in the invitation extended to Dr. Liao. Oppenheimer 33rd Annual Healthcare Conference Date: Monday, March 13 - Wednesday, March 15 Presentation: Tuesday, March 14 (4:00-4:30 p.m. ET) Dr. Liao will present a corporate overview on Tuesday, March 14 at 4:00 - 4:30 p.m. ET (Track 2) and will participate in virtual one-on-one meetings. ABOUT IMMUNE-ONC THERAPEUTICS, INC. Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that reverse immune suppression in the tumor microenvironment. Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development. Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106 (first-in-class antagonist antibody targeting LAIR1), IO-312 (bi-specific antibody targeting LILRB4), and multiple undisclosed programs for solid tumors and hematologic malignancies. Immune-Onc has established agreements with leading biopharmaceutical companies, including BeiGene and Regeneron, to support its global product development plans for IO-108 and IO-202. It has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biopharmaceutical companies. For more information, please visit and follow us on Twitter and LinkedIn.